0001209191-24-004120.txt : 20240229
0001209191-24-004120.hdr.sgml : 20240229
20240229171333
ACCESSION NUMBER: 0001209191-24-004120
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smethurst Dominic
CENTRAL INDEX KEY: 0001820549
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37348
FILM NUMBER: 24705068
MAIL ADDRESS:
STREET 1: C/O BICYCLE THERAPEUTICS PLC
STREET 2: B900, BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc.
CENTRAL INDEX KEY: 0001595097
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464348039
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
BUSINESS PHONE: 617-963-0103
MAIL ADDRESS:
STREET 1: 500 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
FORMER COMPANY:
FORMER CONFORMED NAME: SAV Acquisition Corp
DATE OF NAME CHANGE: 20131220
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-27
0
0001595097
Corbus Pharmaceuticals Holdings, Inc.
CRBP
0001820549
Smethurst Dominic
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE
NORWOOD
MA
02062
0
1
0
0
Chief Medical Officer
0
Common Stock, par value $0.0001 per share
2024-02-27
4
A
0
50000
0.00
A
50000
D
Stock Option (right to buy)
26.07
2024-02-27
4
A
0
50000
0.00
A
2034-02-27
Common Stock
50000
50000
D
On February 27, 2024, the Reporting Person was granted 50,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 27, 2025. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 27, 2025, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 27, 2025.
/s/ Sean Moran, Attorney-in-Fact for Dominic Smethurst
2024-02-29
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Yuval Cohen, Ph.D., Sean Moran and Meghan Houghton his true and
lawful attorney-in-fact to:
1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID,
and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") and the rules thereunder;
2. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete the execution of any such Schedules
13D or 13G, Form ID application for EDGAR codes, and Forms 3, 4 or 5, and the
timely filing of such Forms with the United States Securities and Exchange
Commission and any other authority; and
3. take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the undersigned, including, without
limitation, the execution and filing of a Form 4 with respect to a transaction
which may be reported on a Form 5, it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in his discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform all and every act and thing whatsoever requisite,
necessary and proper to be done in the exercise of any of the rights and powers
herein granted, as fully and to all intents and purposes as he might or could do
in person, with full power of substitution and resubstitution, hereby ratifying
and confirming all that such attorney-in-fact, or his substitute or substitutes,
shall lawfully do or cause to be done by virtue of this Power of Attorney and
the rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming any of the undersigned's responsibilities to
comply with Sections 13 and 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file any Schedules 13D and 13G and Forms 3,
4 and 5 in accordance with Sections 13 and 16(a) of the Exchange Act and the
rules thereunder with respect to the undersigned's holdings of and transactions
in securities issued by Corbus Pharmaceuticals Holdings, Inc., unless earlier
revoked by the undersigned in a signed writing delivered to the foregoing
attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this February 29, 2024.
/s/ Dominic Smethurst
____________________________
By: Dominic Smethurst